The value of this biomarker has been clearly proved in most of second-line trials but also in the frontline setting, with pembrolizumab showing its superiority over platinum doublet chemotherapy in terms of progression-free but also overall survival in patients whose tumor strongly expressed PD-L1 (≥ 50%), establishing it as a new standard of care [3]. This evidence concerns the gene CD274 and neoplasm.